Imatinib mesylate in the treatment of diffuse cutaneous mastocytosis.
Diffuse cutaneous mastocytosis is a less common but potentially life-threatening variant of childhood mastocytosis. Here we report 2 children with diffuse cutaneous mastocytosis in whom an activating somatic KIT mutation was detected. Treatment with imatinib, a KIT inhibitor, resulted in resolution of the lesions and were well tolerated by the patients.
Department of Dermatology, Catholic University of Leuven and University Hospitals Leuven, Leuven, Belgium. Marie-Anne.Morren@uzleuven.be
Marie-Anne
MA
Morren
Anne
A
Hoppé
Marleen
M
Renard
Maria
M
Debiec Rychter
Anne
A
Uyttebroeck
Patrice
P
Dubreuil
Ludovic
L
Martin
D001549:Benzamides; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D007223:Infant; D034701:Mastocytosis, Cutaneous / Q000188:drug therapy*; D010879:Piperazines / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*
D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate